{
  "abstract": "Background Immune checkpoint inhibitors (ICIs) continue to have an increasing role in oncology, offering improved progression-free survival and potential cure, particularly in patients with microsatellite instability-high (MSI-H) tumors and advanced-stage melanoma. Despite improved outcomes, As the use of ICIs expands, exploration into the long-term adverse effects is being analyzed including fertility. 1 This issue is especially pertinent in melanoma, a malignancy with increasing incidence among younger populations. Despite this trend, data remain limited regarding the effects of ICIs on male reproductive health and the frequency and quality of fertility counseling provided to this patient population. The purpose of this study is to characterize the current state of fertility discussions in young male patients with melanoma who have received first-line immunotherapy.Methods A comprehensive electronic database search was conducted for all male patients ages 18-39 with metastatic and locally advanced melanoma patients that were treated with PD-1/PD-L1 therapies between years 2013 and 2024, at the University of Michigan. 38 male patients were subdivided based upon melanoma subtype, BRAF mutational status and ICI regiments. Patients treated with non-immunotherapy drug therapy and chemotherapy were excluded. Data collected included patient-, treatment-, and fertility-related information.Results 38 patients (median age of diagnosis 32) were identified. Complete demographic information was collected ( table 1). 71% of patients had Stage IV melanoma and received combination immunotherapy. 74% of these patients developed at least one IRAE. A discussion of infertility risk or fertility preservation was noted in 27 individuals and referral to fertility preservation clinic was placed for 8 patients. Only one patient had children post-ICI treatment.Conclusions Our study found that although most young males with melanoma treated with ICIs had fertility discussions, few chose to pursue fertility preservation. Ultimately, the cause remains unclear. To further our understanding, we are conducting a comprehensive qualitative assessment to further elucidate the etiology.Reference Ntemou E, et al. Immune checkpoint inhibitors and male fertility: should fertility preservation options be considered before treatment? 17 Mar. 2024. PMID: 38539511.Abstract 725 Table 1Clinical, treatment, toxicity, and fertility characteristics of young male melanoma patients treated with immune checkpoint inhibitors (n=38)",
  "authors": [
    {
      "affiliations": [
        "University of Michigan, Ann Arbor, MI, USA"
      ],
      "name": "Haadi Ali"
    },
    {
      "affiliations": [
        "University of Michigan, Ann Arbor, MI, USA"
      ],
      "name": "Ellen Wold"
    },
    {
      "affiliations": [
        "University of Michigan, Ann Arbor, MI, USA"
      ],
      "name": "Tarek Haykal"
    },
    {
      "affiliations": [
        "University of Michigan, Ann Arbor, MI, USA"
      ],
      "name": "Victoria Wytiaz"
    },
    {
      "affiliations": [
        "University of Michigan, Ann Arbor, MI, USA"
      ],
      "name": "Peter Dawood"
    }
  ],
  "title": "725 Fertility concerns and outcomes among adolescent and young adult males with melanoma receiving immunotherapy",
  "uid": "758a40c8-df08-570e-8a9b-eaba12690f74"
}